NDAORALTABLET
Lifecycle
Pre-Launch
Data completeness
1/8 — Limited
DISOPHROL (dexbrompheniramine maleate; pseudoephedrine sulfate) by Merck & Co.. Approved for nasal congestion due to the common cold, hay fever, other upper repiratory allergies helps decongest sinus opening and 5 more indications.
Drug data last refreshed 12h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DISOPHROL is a combination oral tablet containing dexbrompheniramine maleate (an H1-receptor antagonist antihistamine) and pseudoephedrine sulfate (a sympathomimetic nasal decongestant). It treats nasal congestion, hay fever, and upper respiratory allergies by reducing swelling of nasal passages and shrinking engorged membranes. The drug works by blocking histamine receptors to reduce allergic symptoms while vasoconstricting nasal blood vessels to relieve congestion.
Pre-Launch
Pre-launch status indicates immediate opportunity for launch team roles; career trajectory depends on market adoption relative to entrenched competitors.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (8)
Worked on DISOPHROL at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.